A review on the current status of retinal prostheses (bionic eye)

• Published in: Medicina fluminensis 2019-06, Vol.55 (2), p.159-166
• Main Authors: Pelčić, Goran, Brumini, Martina, Crnković, Ivana, Alpeza-Dunato, Zvjezdana, Čaljkušić-Mance, Tea, Brumini, Ivan
• Format: Article
• Language: English
• ISSN: 1847-6864; 1848-820X
• DOI: 10.21860/medflum2019_218809

Argus® II prva je retinalna proteza odobrena za liječenje slijepih pacijenata koji boluju od retinalne pigmentoze. Godine 2011. primila je oznaku CE-a (engl. European Committee) te 2013. odobrenje FDA-a (engl. Food and Drug Administration). Retinalna proteza pruža stabilnu, sigurnu i dugotrajnu retinalnu stimulaciju. Poboljšanje vida s retinalnim protezama ovisi o poboljšanju vidne rezolucije, razvoju točnog neuralnog obrasca za obradu slike i poboljšanju biološke kompatibilnosti uređaja kako bi se osigurala dugotrajnost. Jednom tema narodne predaje i znanstvene fantastike, ideja povratka vida slijepim osobama danas se približava realnosti. Argus® II, the first retinal prosthesis is approved for the treatment of patients with retinal pigmentosis. 2011 has received the CE (European Committee) designation and 2013 FDA (Food and Drug Administration) Approval. Retinal prosthesis provides a stable, safe and long-lasting retinal stimulation. The improvement of vision with retinal prosthesis depends on the improvement of the visual resolution, development of the correct neural form for imaging and improvement of the biological compatibility of the device to ensure durability. Once the theme of folklore and science fiction, the idea of returning sight to blind people today is approaching reality.